glp 1 weight loss drug Patients' Use GLP-1 Drugs for Loss, Benefit Gains GLP-1 Agonists Weight Loss Drugs

This amount of weight loss has not been accomplished before with medical therapy

The Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market worth USD 2.91 billion in 2026 is growing at a CAGR of 8.24% to reach USD 4.33 billion by 2031

GLP-1 medications are changing how people think about weight loss and how they actually lose weight, driving changes in views about obesity care among health systems and providers and affecting the broader US economy. These drugs hold the potential to help address what continues to be an increasing obesity problem in the US. A 2024 []

Discover how GLP-1 and GLP-1/GIP therapies (semaglutide and tirzepatide) influence body composition

This supplement fits seamlessly into any lifestyle, encouraging regular use alongside balanced nutrition and active habits to help maximize sustainable, long-term wellness results.